Sign In
29 Jan 2010 07:00
Cyprotex PLC
('Cyprotex' or 'the Company')
Trading Update and Notice of Results
Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, announces a trading update on its performance in the calendar year ending 31 December 2009.
Following the Company's announcement on 20 November 2009, the Company confirms a solid level of activity in the months of November and December 2009, and as a result the Directors expect to report full year 2009 results to be in line with market expectations.
Cyprotex expects to report its final year end results to December 2009 on 17 March 2010.
For further information:
|
Cyprotex PLC |
Tel: +44 (0) 1625 505 100 |
|
|
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer |
||
|
ir@cyprotex.com |
www.cyprotex.com |
|
|
Noble & Company |
Tel: +44 (0) 20 7763 2200 |
|
|
John Llewellyn-Lloyd Sam Reynolds sam.reynolds@noblegp.com |
www.noblegp.com |
|
|
Financial Dynamics |
Tel: +44 (0) 20 7831 3113 |
|
|
Ben Brewerton / Ben Atwell / John Dineen |
||
|
cyprotex@fd.com |
www.fd.com |
|
Follow the stocks
